VARSITY: Better Outcomes With Vedolizumab Than Adalimumab in UC VARSITY: Better Outcomes With Vedolizumab Than Adalimumab in UC

In patients with moderate to severe ulcerative colitis, treatment with vedolizumab leads to better histologic outcomes than treatment with adalimumab, according to findings from the VARSITY trial.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news